Evidence map›Paper›PMID 9007991›Full record

ArticleProtein science : a publication of the Protein Society1997

gamma-Carboxyglutamic acids 36 and 40 do not contribute to human factor IX function.

S Gillis, B C Furie, B Furie, H Patel, M C Huberty, M Switzer, W B Foster, H A Scoble, M D Bond

Open access · bronzeAbstract read
In one paragraph

Article in Protein science : a publication of the Protein Society, 1997. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
1.5field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 53 citations in OpenAlex.

  1. Article
  2. Review
  3. Multiplex, multimodal mapping of variant effects in secreted proteins.bioRxiv : the preprint server for biology · 2025
    Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Review
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 2 institutions in 1 country.

S GillisDivision of Hematology-Oncology, New England Medical Center, Boston, Massachusetts 02111, USA.
B C Furie
B Furie
H Patel
M C Huberty
M Switzer
W B Foster
H A Scoble
M D Bond
Tufts University · USTufts Medical Center · US

Funding

STRUCTURE OF THE VITAMIN K-DEPENDENT CARBOXYLASEP01HL042443 · NHLBI · TUFTS MEDICAL CENTER · PI FURIE, BARBARA C · 1989 to 2003
$7.4M
METAL-DEPENDENT COMPLEXES IN BLOOD COAGULATIONR01HL018834 · NHLBI · TUFTS MEDICAL CENTER · PI FURIE, BARBARA C · 1985 to 2002
$1.4M
BIOSYNTHESIS OF BLOOD CLOTTING PROTEINSR01HL038216 · NHLBI · TUFTS MEDICAL CENTER · PI FURIE, BRUCE · 1997 to 2001
$607k
METAL-DEPENDENT COMPLEXES IN BLOOD COAGULATIONR37HL018834 · NHLBI · TUFTS MEDICAL CENTER · PI FURIE, BARBARA C · 1988 to 1997
–
BIOSYNTHESIS OF BLOOD CLOTTING PROTEINSR37HL038216 · NHLBI · TUFTS MEDICAL CENTER · PI FURIE, BRUCE · 1987 to 1996
–
NHLBI NIH HHS HL 18834NHLBI NIH HHS HL 38216NHLBI NIH HHS HL 42443
6 · The paper itself

Abstract

The gamma-carboxyglutamic acid (Gla) domains of the vitamin K-dependent blood coagulation proteins contain 10 highly conserved Gla residues within the first 33 residues, but factor IX is unique in possessing 2 additional Gla residues at positions 36 and 40. To determine their importance, factor IX species lacking these Gla residues were isolated from heterologously expressed human factor IX. Using ion-exchange chromatography, peptide mapping, mass spectrometry, and N-terminal sequencing, we have purified and identified two partially carboxylated recombinant factor IX species; factor IX/gamma 40E is uncarboxylated at residue 40 and factor IX/gamma 36,40E is uncarboxylated at both residues 36 and 40. These species were compared with the fully gamma-carboxylated recombinant factor IX, unfractionated recombinant factor IX, and plasma-derived factor IX. As monitored by anti-factor IX:Ca (II)-specific antibodies and by the quenching of intrinsic fluorescence, all these factor IX species underwent the Ca(II)-induced conformational transition required for phospholipid membrane binding and bound equivalently to phospholipid vesicles composed of phosphatidylserine, phosphatidylcholine, and phosphatidylethanolamine. Endothelial cell binding was also similar in all species, with half-maximal inhibition of the binding of 125I-labeled plasma-derived factor IX at concentrations of 2-6 nM. Functionally, factor IX/gamma 36,40E and factor IX/gamma 40E were similar to fully gamma-carboxylated recombinant factor IX and plasma-derived factor IX in their coagulant activity and in their ability to participate in the activation of factor X in the tenase complex both with synthetic phospholipid vesicles and activated platelets. However, Gla 36 and Gla 40 represent part of the epitope targeted by anti-factor IX:Mg(II)-specific antibodies because these antibodies bound factor IX preferentially to factor IX/gamma 36,40E and factor IX/gamma 40E. These results demonstrate that the gamma-carboxylation of glutamic acid residues 36 and 40 in human factor IX is not required for any function of factor IX examined.

Indexed as

1-Carboxyglutamic AcidAmino Acid SequenceAnimalsCattleCells, CulturedChromatography, High Pressure LiquidChromatography, Ion ExchangeEndothelium, VascularFactor IXHumansMolecular Sequence DataPeptide MappingProtein BindingRecombinant ProteinsSpectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization1-Carboxyglutamic AcidFactor IXRecombinant Proteins

Identifiers

PMID9007991
PMCPMC2143515
OpenAlexW1996716984

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.